CN1367778A - 新型的具有5,6取代嘧啶环的羧酸衍生物、其制备方法和作为内皮素受体拮抗药的用途 - Google Patents

新型的具有5,6取代嘧啶环的羧酸衍生物、其制备方法和作为内皮素受体拮抗药的用途 Download PDF

Info

Publication number
CN1367778A
CN1367778A CN00810533A CN00810533A CN1367778A CN 1367778 A CN1367778 A CN 1367778A CN 00810533 A CN00810533 A CN 00810533A CN 00810533 A CN00810533 A CN 00810533A CN 1367778 A CN1367778 A CN 1367778A
Authority
CN
China
Prior art keywords
alkyl
phenyl
group
cooh
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00810533A
Other languages
English (en)
Chinese (zh)
Inventor
W·安伯格
G·科特斯乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of CN1367778A publication Critical patent/CN1367778A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CN00810533A 1999-07-20 2000-07-05 新型的具有5,6取代嘧啶环的羧酸衍生物、其制备方法和作为内皮素受体拮抗药的用途 Pending CN1367778A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933164.2 1999-07-20
DE19933164A DE19933164A1 (de) 1999-07-20 1999-07-20 Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten

Publications (1)

Publication Number Publication Date
CN1367778A true CN1367778A (zh) 2002-09-04

Family

ID=7914884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00810533A Pending CN1367778A (zh) 1999-07-20 2000-07-05 新型的具有5,6取代嘧啶环的羧酸衍生物、其制备方法和作为内皮素受体拮抗药的用途

Country Status (21)

Country Link
EP (1) EP1196394A1 (cs)
JP (1) JP2003505377A (cs)
KR (1) KR20020019550A (cs)
CN (1) CN1367778A (cs)
AR (1) AR030026A1 (cs)
AU (1) AU6561500A (cs)
BG (1) BG106321A (cs)
BR (1) BR0012592A (cs)
CA (1) CA2379545A1 (cs)
CZ (1) CZ2002190A3 (cs)
DE (1) DE19933164A1 (cs)
HU (1) HUP0202646A3 (cs)
IL (1) IL147666A0 (cs)
MX (1) MXPA02000616A (cs)
NO (1) NO20020254L (cs)
PL (1) PL353165A1 (cs)
SK (1) SK772002A3 (cs)
TR (1) TR200200622T2 (cs)
TW (1) TW555749B (cs)
WO (1) WO2001005771A1 (cs)
ZA (1) ZA200200333B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462065T3 (es) * 2009-07-10 2014-05-22 Cadila Healthcare Limited Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este
CA2792473A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited A process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
PL340871A1 (en) * 1997-10-31 2001-03-12 Basf Ag Novel derivatives of carboxylic with admidic side chains, method of obtaining them and application of such novel derivatives as antagonists of endothelin rceptors

Also Published As

Publication number Publication date
AU6561500A (en) 2001-02-05
TR200200622T2 (cs) 2002-06-21
HUP0202646A3 (en) 2003-03-28
CZ2002190A3 (cs) 2003-08-13
JP2003505377A (ja) 2003-02-12
IL147666A0 (en) 2002-08-14
HUP0202646A2 (hu) 2003-02-28
BG106321A (en) 2002-08-30
NO20020254L (no) 2002-02-20
ZA200200333B (en) 2003-04-30
CA2379545A1 (en) 2001-01-25
EP1196394A1 (de) 2002-04-17
BR0012592A (pt) 2002-05-28
DE19933164A1 (de) 2001-01-25
AR030026A1 (es) 2003-08-13
MXPA02000616A (es) 2002-08-30
TW555749B (en) 2003-10-01
KR20020019550A (ko) 2002-03-12
NO20020254D0 (no) 2002-01-17
PL353165A1 (en) 2003-10-20
WO2001005771A1 (de) 2001-01-25
SK772002A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
CN1923820A (zh) 新的羧酸衍生物，其制备和应用
CN1093535C (zh) 咪唑衍生物
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1323203A (zh) Fc受体调节剂及其应用
CN1554649A (zh) 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
CN1789246A (zh) 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
CN1694708A (zh) TGFβ的抑制剂
CN1209063A (zh) 玻连蛋白受体拮抗剂
CN1284944A (zh) 整联蛋白受体拮抗剂
CN1238689A (zh) 玻连蛋白受体拮抗剂
CN1700918A (zh) 关于hiv整合酶的n－取代的羟基嘧啶酮甲酰胺抑制剂
CN1209744A (zh) 玻连蛋白受体拮抗剂
CN1726196A (zh) 基于吡嗪的微管蛋白抑制剂
CN1681784A (zh) 作为霉蝇碱受体拮抗剂的氮杂二环衍生物
CN1107158A (zh) 多取代的2-氨基-噻唑衍生物
CN1132511A (zh) 基质金属蛋白酶抑制剂
CN1599720A (zh) 作为g－蛋白偶联受体(gpcr)的配体的四氢咔唑衍生物
CN1047084A (zh) 具有酶抑制作用的二肽衍生物
CN1225465C (zh) 新化合物
CN1200729A (zh) 用作止痛剂的旋光苯基嘧啶衍生物
CN1251991A (zh) 新的羧酸衍生物,它们的制备以及在癌症治疗方面的用途
EA022345B1 (ru) Производные арилпиразинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
CN1282322A (zh) 1,4－二氮杂环庚烷衍生物
HK1048317A (en) Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
CN1107054C (zh) 2,4'－联吡啶基衍生物的制备方法和分离方法及其应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1048317

Country of ref document: HK